By Sabela Ojea


Argenx said the Food and Drug Administration has approved Vyvgart Hytrulo to treat adults with chronic inflammatory demyelinating polyneuropathy.

The company on Friday said Vyvgart Hytrulo has been approved as a once weekly 30- to 90-second subcutaneous injection.

Chronic inflammatory demyelinating polyneuropathy is a rare, debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system.


Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix


(END) Dow Jones Newswires

06-21-24 1802ET